

Edgar Filing: INTERLEUKIN GENETICS INC - Form 8-K

INTERLEUKIN GENETICS INC

Form 8-K

December 10, 2002

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)  
OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): December 10, 2002

INTERLEUKIN GENETICS, INC.  
(Exact name of registrant as specified in its charter)

Delaware	000-23413	94-3123681
-----	-----	-----
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

135 Beaver Street, Waltham, MA 02452  
-----  
(Address of principal executive offices)

Registrant's telephone number, including area code: (781) 398-0700  
-----

Item 5. Other Events.

On December 10, 2002, Interleukin Genetics, Inc. publicly disseminated a press release announcing that its common stock would be delisted from the Nasdaq Stock Market effective with the open of business on December 10, 2002. The information contained in the press release is incorporated herein by reference and filed as Exhibit 99.1 hereto

Item 7. Financial Statements and Exhibits.

(c) Exhibit

99.1 Press Release dated December 10, 2002

SIGNATURES

Edgar Filing: INTERLEUKIN GENETICS INC - Form 8-K

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

INTERLEUKIN GENETICS, INC.  
-----

(Registrant)

Date: December 10, 2002  
-----

/s/ Fenel M. Eloi  
-----

Fenel M. Eloi, Chief Operating Officer,  
Chief Financial Officer, Treasurer and  
Secretary and Treasurer